Clinical Trial Update: Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating adjuvant metronomic capecitabine in combination with endocrine therapy for HR+/HER2- primary breast cancer and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING